Claims for Patent: 6,162,812

Summary for Patent: 6,162,812

Title:	Pharmaceutical compositions containing HIV protease inhibitors and methods of their use
Abstract:	HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
Inventor(s):	Dressman; Bruce A. (Indianapolis, IN), Fritz; James E. (Greenwoode, IN), Hammond; Marlys (Pasadena, CA), Hornback; William J. (Indianapolis, IN), Kaldor; Stephen W. (Indianapolis, IN), Kalish; Vincent J. (San Diego, CA), Munroe; John E. (Indianapolis, IN), Reich; Siegfried Heinz (San Diego, CA), Tatlock; John H. (Poway, CA), Shepherd; Timothy A. (Indianapolis, IN), Rodriguez; Michael J. (Indianapolis, IN)
Assignee:	Agouron Pharmaceuticals, Inc. (La Jolla, CA)
Application Number:	09/283,152
Patent Claims:	1. A pharmaceutical composition comprising: (a) an effective amount of a compound of the formula ##STR132## or a prodrug or pharmaceutically acceptable salt of said compound; and (b) a pharmaceutically acceptable carrier. 2. A pharmaceutical composition according to claim 1, wherein said compound, prodrug, or pharmaceutically acceptable salt (a) is a stereoisomer of the formula: ##STR133## or a prodrug or pharmaceutically acceptable salt of said steroisomer. 3. A pharmaceutical composition according to claim 2, wherein said compound, prodrug, or pharmaceutically acceptable salt (a) is said stereoisomer of the formula: ##STR134## 4. A pharmaceutical composition according to claim 2, wherein said compound, prodrug, or pharmaceutically acceptable salt (a) is a pharmaceutically acceptable salt of the formula: 5. A method of inhibiting HIV protease comprising administering to a host an effective amount of a compound of the formula: or a prodrug or pharmaceutically acceptable salt of said compound. 6. A method according to claim 5 wherein said compound, prodrug or pharmaceutically acceptable salt is a stereoisomer of the formula: ##STR135## or a prodrug or pharmaceutically acceptable salt of said stereoisomer. 7. A method according to claim 6 wherein said compound, prodrug or pharmaceutically acceptable salt is said stereoisomer of the formula: ##STR136## 8. A method according to claim 6 wherein said compound, prodrug or pharmaceutically acceptable salt is a pharmaceutically acceptable salt of the formula: